Antagomir-27b treatments significantly reverse changes in its target gene PPAR-γ expression caused by pressure overload in the myocardium, and attenuate TAC-induced cardiac hypertrophy, interstitial fibrosis, and cardiac dysfunction, suggesting that miR-27b is a novel therapeutic target for pathological cardiac hypertrophy [30]. Here, PPARG is linked to cardiac hypertrophy.